We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Abemaciclib Reduces Recurrence in High-Risk Hormone Receptor Positive Early Breast Cancer

News   Sep 21, 2020 | Original story from ESMO

 
Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer
 
 
Advertisement
 

RELATED ARTICLES

Drug That Targets Challenging Cancer Mutation Could Treat Several Tumor Types

News

A new clinical trial shows a novel drug designed to counter the effects of an important cancer mutation could be effective against a range of tumor types including lung and gynecological cancers.

READ MORE

Turning the Virus’ RBD Into a Nanoparticle an Appealing Approach for COVID-19 Vaccine

News

A University at Buffalo-led research team has discovered a technique that could help increase the effectiveness of vaccines against the novel coronavirus, the virus that causes COVID-19.

READ MORE

Deep Learning Model Helps Drug Developers Target SARS-CoV-2's Main Protease

News

Researchers have deployed a machine learning model to help drug developers on their most promising leads for attacking one of the virus’ most compelling targets –SARS-CoV-2's main protease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE